News & Views

Telix today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis.

Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise.

Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in the Journal of Nuclear Medicine. TLX400 demonstrated clinical antitumor activity with a manageable safety profile in subjects with advanced sarcoma, a patient population with limited treatment options

Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona from 4 – 8 October 2025.

Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging agent for prostate cancer.

Telix today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis.

Telix today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis.

Telix today announces that it has reached agreement with the United States (U.S.) Food and Drug Administration (FDA) regarding resubmission of its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer. As previously advised, the Company confirms its plan to resubmit the NDA during Q4 2025.

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Spain by AEMPS for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. Illuccix® is now approved in all 19 countries included in Telix’s decentralized procedure (DCP) submitted in Europe.

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.